Antares pharma inc.

Follow. EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug ...

Antares pharma inc. Things To Know About Antares pharma inc.

using Antares auto injector technology •~75% of all commercial lives covered • 18 Orange Book listed patents extending to 2038 •FY 2021 revenue of $62.2M, up 34% year-over-year XYOSTED® TLANDO™ •Oral testosterone replacement therapy (TRT) •Granted FDA approval on March 28, 2022 and commercially launched in June 2022 •2X/daily ...Get the latest Antares Pharma Inc. (ATRS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.May 19, 2022 ... Acquisition | ANTARES PHARMA INC | 25th May 2022 · ANTARES PHARMA INC will be removed from the Index. · The weight of ANTARES PHARMA INC (ATRS.Mar 2, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... 25. 4. 2022 ... FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., ...

Mar 4, 2019 · Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto ...

Apr 14, 2022 · Credit: Arek Socha from Pixabay. Halozyme Therapeutics has signed a definitive agreement for the acquisition of all of the outstanding shares of Antares Pharma in a deal valued at nearly $960m or $5.60 for each share, in cash. A speciality pharmaceutical firm, Antares focuses on developing pharmaceutical products and technologies to address ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic …

Device Type: Auto-Injector: Dosage Type: Fixed: Injection Volume: 0.2-1.0ml Injection Type: SC or IM: Primary Container: 1.0ml long prefilled syringeEWING, N.J., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that today it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ...Antares Pharma, Inc., a leader in self-injection drug delivery technology, announced the latest advancement in its proprietary line of VIBEX(TM) auto-injectors. Antares’ new VIBEX QS auto-injector platform offers a dose capacity of 1 mL and greater in a compact design. VIBEX QS achieves this advance by incorporating a novel triggering ...23. 5. 2022 ...ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) _____ Delaware: 1-32302: 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South, Suite 300, Ewing, ...

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …

Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ...

Abstract. Medi-Ject Corporation (now Antares Pharma, Inc.) has been providing delivery devices for the needle-free administration of insulin for over 25 years. This study was one of the final steps in the development and premarket evaluation of Medi-Ject's newest needle-free system, the Medi-Jector Vision. This study was conducted to evaluate ... SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. …A copy of Antares Pharma, Inc.’s (the “Company”) updated investor presentation slides that the Company intends to use effective immediately is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.. The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall …Antares Pharma, Inc. (Nasdaq - ATRS) Under the terms of the agreement, Antares will be acquired by Halozyme Therapeutics, Inc. (“Halozyme”) (Nasdaq - HALO). Antares stockholders will receive ...Antares Pharma Inc. announced that Ferring Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON (somatropin [rDNA origin]) for injection, and the needle-free delivery system to be …Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc , the …Jan 25, 2022 · Antares Pharma Inc. Serghei Lungu v. Antares Pharma Inc, No. 21-1624 (3d Cir. 2022) Annotate this Case. Download PDF. Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes. This site is protected by reCAPTCHA and the ...

Antares Pharma, Inc. Website. Get a D&B Hoovers Free Trial. Overview Company Description: Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need …Tiberend Strategic Advisors, Inc. Jason Rando. (212) 827-0020. [email protected]. Share. Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...View Antares Pharma, Inc. Marketing Contacts, Executives, Media Spend, Marketing Technologies and Brands. Open doors with marketers, their agencies and the ...Antares Pharma, Inc. (Amex:AIS) has elected Leonard S. Jacob, M.D., Ph.D. to the Company ' s Board of Directors.. Dr. Leonard Jacob joins Antares with over 29 years of pharmaceutical industry experience including having founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its …Jan 11, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Get the latest Antares Pharma Inc. (ATRS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Delaware . 1-32302 . 41-1350192 (State or other jurisdiction. of incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...References: 1. NOCDURNA prescribing information: Ferring Pharmaceuticals Inc. Please see Prescribing Information including important safety information and boxed warning. * Source: Bloomberg/Symphony Health Solutions 0 100 200 300 400 500 600 700 800 NOCDURNA® Monthly TRx* NRx Refills Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Delaware . 1-32302 . 41-1350192 (State or other jurisdiction. of incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma's (NASDAQ:ATRS) stock up by 8.0% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

View Antares Pharma, Inc. Marketing Contacts, Executives, Media Spend, Marketing Technologies and Brands. Open doors with marketers, their agencies and the ...

Assignee(s): Antares Pharma, Inc. A jet injector that includes a prefilled syringe. The syringe includes a fluid chamber that contains a medicament. The syringe also has an injection-assisting needle, and a plunger is movable within the fluid chamber. A housing is configured for allowing insertion of the needle to a penetration depth. An …

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic …13. 4. 2022 ... Antares Pharma to be acquired by Halozyme in $960M deal ... Robert Apple, CEO of Antares Pharma. ... Antares, which was originally founded in Exton, ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate …Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Lincare Inc. sells oxygen and infusion systems for in-home respiratory therapy. Some of the oxygen systems include concentrators, portable and stationary liquid oxygen systems and high-pressure systems.Mar 29, 2022 · Follow. EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug ... Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.Plaintiff–Appellant Antares Pharma, Inc. (“Antares”) appeals from a decision of the United States District Court for the District of Delaware denying Antares' motion for preliminary injunction. Antares seeks to enjoin alleged infringement of claims 31, 34, 35, and 37 of a reissue patent, RE44, 846 (“the '846 patent”).Delaware . 1-32302 . 41-1350192 (State or other jurisdiction. of incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...On April 12, 2022, Antares Pharma, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Halozyme Therapeutics, Inc., a Delaware corporation (“ Halozyme ”), and Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Halozyme ...

Halozyme Therapeutics Inc. agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on drug delivery. Halozyme on ...As previously disclosed, on February 28, 2014, Antares Pharma, Inc. (“Antares”) sued Medac Pharma, Inc. (“Medac”) and its foreign parent, medac GmbH, in the United States District Court for the District of Delaware alleging infringement. Antares is asserting four patents. On March 14, 2014, Antares filed a motion for preliminary injunction seeking to …Instagram:https://instagram. scotts liquid goldtrading microge pensiondata center reits etf Jan 26, 2016 · Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. what is the cheapest way to invest in goldvalue of a mercury dime SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”). The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May ... Antares Pharma, Inc. (Amex:AIS) has elected Leonard S. Jacob, M.D., Ph.D. to the Company ' s Board of Directors.. Dr. Leonard Jacob joins Antares with over 29 years of pharmaceutical industry experience including having founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its … curlf stock price About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several …Symbol Techs., Inc. v. Lemelson Med., 277 F.3d 1361, 1366 (Fed. Cir. 2002). 7 12 ANTARES PHARMA INC. v. MEDAC PHARMA INC. different from the 1870 Act with regard to claiming, reissue, and the role of the PTO,” and that “[s]uch minor differences as exist between those provisions in the 1870 and the 1952 Acts have no bearing on [our …Minnetonka, Minnesota (763) 475-7700 12500 Whitewater Drive Minnetonka, MN 55343 USA